Long-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3)

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the United States. Long-acting muscarinic antagonists (LAMAs) are a class of medications used as maintenance therapy for COPD. The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrrolate (GLY) 15.6 μg twice daily (b.i.d.), compared with an approved long-acting β2-agonist (LABA), indacaterol (IND) 75 μg once daily (q.d.) in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation.

Source: Respiratory Medicine CME - March 21, 2016 Category: Respiratory Medicine Authors: Donald A. Mahler, Alex H. Gifford, Aditi Satti, Nicola Jessop, Joerg H. Eckert, Peter D'Andrea, Fernando Mota, Rudrani Banerjee Source Type: research